NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Nivalis Therapeutics, Inc. (“Nivalis Therapeutics” or the “Company”) (NASDAQ:NVLS) concerning possible violations of federal securities laws by certain officers and directors.
On November 28, 2016, Nivalis Therapeutics announced that the Company’s Phase 2 Trial of Cavosonstat failed to meet its primary endpoint of demonstrating a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, in comparison to placebo. Following this news, shares of Nivalis Therapeutics were down more than 59% on intraday trading on November 29, 2016. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.